News and Comments

INCYTE: SHOWS ITS PATH TOWARDS GROWTH

  Wednesday, February 12, 2014

 More...

HALOZYME: FINANCING PEGPH20 IS WORTH RAISING MONEY

  Wednesday, February 05, 2014

Halozyme Therapeutics (HALO) stock has been a loser yesterday while other biotech firms have rebounded after dipping during the few days’ of an angry market. The reason for the stock decline was the announcement of pricing of Halozyme’s previously announced underwritten public offering of 7,692,307 shares of its common stock at a public offering price of $13.00 per share.  More...


Recent News_and_Comments


Archive


Tags